|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Craniosynostosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A logistic model was used to analyze the association of severe CRS incidence with CAR-T dose and baseline factors including age and baseline tumor burden.
|
31428935 |
2019 |
|
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of note, we also found that the genetic inactivation of GMCSF does not impair the antitumor function or proliferative capacity of CAR T-cells <i>in vitro</i> We conclude that it is possible to prevent CRS by using "all-in-one" GMCSF-knockout CAR T-cells.
|
30804212 |
2019 |
|
Craniosynostosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokine release syndrome (CRS) is a common and potentially fatal complication of CAR-T cell therapy.
|
29443792 |
2018 |
|
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytokine release syndrome (CRS) remains to be a major adverse effect of chimeric antigen receptor T (CAR-T) cell therapy in B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma.
|
30198955 |
2019 |
|
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical experience with the anti-CD19 CAR T cell therapy tisagenlecleucel at the University of Pennsylvania (Penn) was used to develop the Penn grading scale for CRS.
|
29499750 |
2018 |
|
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current research suggests that patients with a higher disease burden and higher CAR-T cell doses are positively associated with the development of ICANS, as are elevated serum levels of proinflammatory cytokines and the presence of cytokine release syndrome (CRS).
|
31327064 |
2019 |
|
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytokine release syndrome (CRS) severity was the only factor after CAR-T-cell infusion associated with infection in a multivariable analysis.
|
29038338 |
2018 |
|
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent data suggest that monocytes and macrophages contribute to the development of CRS and neurotoxicity after CAR-T cell therapy.
|
30463995 |
2019 |
|
Craniosynostosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the clinic, chimeric antigen receptor-modified T (CAR T) cell therapy is frequently associated with life-threatening cytokine-release syndrome (CRS) and neurotoxicity.
|
29808007 |
2018 |
|
Craniosynostosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Areas covered</b>: CAR-T cell associated toxicities include cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES), alternatively known as immune effector cell-associated neurotoxicity syndrome (ICANS).
|
31219357 |
2019 |
|
Craniosynostosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokine release syndrome (CRS) and CAR-T-associated encephalopathy syndrome (neurotoxicity) are the most common adverse effects associated with CAR-T therapy.
|
30560413 |
2019 |
|
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy.
|
31055613 |
2019 |
|
Craniosynostosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this review we discuss some of the mechanistic contributions intrinsic to the CAR-T construct, the tumor being treated, and the individual patient that impact the development and severity of CRS and neurotoxicity.
|
31355491 |
2019 |
|
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
T cell-based therapies (blinatumomab and CAR T cell therapy) have produced unprecedented responses in relapsed and refractory (r/r) acute lymphoblastic leukemia (ALL) but is accompanied with significant toxicities, of which one of the most common and serious is cytokine release syndrome (CRS).
|
30666425 |
2019 |
|
Craniosynostosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES) are common, predictable and potentially lethal side effects.
|
30072559 |
2018 |
|
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specific toxicities related to CAR-T like Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) could be fatal and need close monitoring and prompt treatment to avoid mortality and improve efficacy of the treatment.
|
31177852 |
2019 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By flow cytometric analysis, H1299 (lung) and SW620 (colorectal) tumor cells showed high levels of CAR expression, whereas LN444 (glioblastoma), LNZ308 (glioblastoma), and H1299-R5 (lung) tumor cells were negative for CAR expression.
|
15735729 |
2005 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggested that tumor-selective, bitargeted anti-EGFR/EGFRvIII CAR T cells may be a promising modality for the treatment of patients with EGFR/EGFRvIII-overexpressing glioblastoma.<i></i>.
|
30201736 |
2018 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A single dose of peripherally infused CAR T cells cleared antigen-expressing tumor cells in patients with glioblastoma, a 10-person trial found.
|
28754782 |
2017 |
|
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Targeting Glioblastoma with CAR T Cells.
|
28108463 |
2017 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adoptive cell therapy (ACT) using T cells engineered with chimeric antigen receptor (CAR) targeting an ideal molecular marker in GBM, e.g. epidermal growth factor receptor type III (EGFRvIII) has demonstrated a satisfactory efficacy in treating malignant brain tumors.
|
28302023 |
2017 |
|
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We then tested the antitumor activity of B7-H3-redirected CAR-T cells against GBM cell lines and patient-derived GBM neurospheres in vitro and in xenograft murine models.
|
31466914 |
2019 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A first-in man exploratory study evaluating EGFRvIII-specific CAR T cells for patients with newly diagnosed glioblastoma demonstrated overall safety of CAR T cell therapy and effective target recognition.
|
29666934 |
2018 |
|
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we discuss effects of the GB tumor microenvironment on NK-cell functionality, summarize early treatment attempts with <i>ex vivo</i> activated NK cells, and describe relevant CAR target antigens validated with CAR-T cells.
|
31798595 |
2019 |